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To the Editor:
We read with great interest the arti-
cle by Bylicki et al.1 on the multimodal 
management of solitary fibrous tumors 
of the pleura (SFTP). The authors present 
a multi-institutional series of 68 patients 
with SFTP, spanning a wide spectrum of 
presentation from localized to metastatic 
disease. They describe in detail applied 
perioperative therapies and follow-up 
data to illustrate treatment efficacy, 
which unfortunately was limited. The 
authors also highlight the importance of 
the classification proposed by de Perrot et 
al.2 in the decision making for the admin-
istration of adjuvant therapies.
Excluding patients with metastatic 
disease (n = 9), there were 59 patients 
who underwent resection of SFTP as the 
primary treatment. Of these, five (8.5%) 
received perioperative treatments, 
mostly chemotherapy. Recurrence was 
observed in 18 (30.5%) patients with 
localized SFTP. Regardless of their 
stage classification, recurrence rates 
were extraordinarily high and not con-
gruent with previous published series 
(recurrence: 4–15%)2–5; this observation 
seemed driven by the recurrence of 52% 
in de Perrot stage II tumors, which may 
invoke the completeness of resection. 
Unfortunately, it is not possible to dis-
cern from the study how many patients 
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with localized SFTP underwent incom-
plete resection, and the impact this may 
have contributed to recurrence.
On the other hand, the authors 
stress the importance of the classification 
proposed by de Perrot et al.,2 not only as 
a prognostic factor but also as a guideline 
for adjuvant interventions. It should be 
noted that this classification was based 
on a nonsystematic literature review, and 
despite its prognostic value, corroborated 
by the authors1 and others, its validity to 
guide management after SFTP resection 
has yet to be proven. Moreover, manage-
ment recommendations derived from this 
classification2 were intended after com-
plete resection, as patients with incom-
plete resections are at a higher risk for 
recurrence. Therefore, it is not surprising 
that adjuvant chemotherapy was given to 
six of seven patients with tumor invasion 
at the resection margins, regardless of 
their de Perrot classification.
Recently, a scoring system was pro-
posed for the prediction of SFTP recur-
rence after complete resection3 and was 
later validated in an independent European 
population.4 This score combines six 
macroscopic and histopathologic tumor 
characteristics to classify patients accord-
ing to their risk of recurrence with excel-
lent predictive capacity, outperforming 
both the use of England’s criteria and de 
Perrot’s classification. A recent indepen-
dent, multi-institutional series of patients 
with SFTP5 found this scoring system to 
provide better discrimination compared 
with previously published classifications. 
In addition, this score has been associated 
with the extent of surgery, use of adjuvant 
therapies, and overall survival.4 This scor-
ing system was first published in 20133 
and should be carefully considered by the 
authors to assess risk of recurrence in the 
analysis of their patient population. Better 
prognostic models, such as the one men-
tioned here,3,4 may result in better stratifi-
cation of patients according to their risk of 
recurrence. This would result in improved 
selection of those patients at the highest 
risk for SFTP recurrence for adjuvant 
interventions, clinical trials, or stricter 
postoperative surveillance protocols.
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Tapias and Dr. Lanuti for their 
The response below published pre-
viously in the June 2015 issue. It is 
republished below to appear  
with the Letter to the Editor by  
Drs. Tapias and Lanuti.
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